Role of RRM1 in the Treatment and Prognosis of Advanced Non-small Cell Lung Cancer

VernacularTitle:核苷酸还原酶M1在晚期非小细胞肺癌治疗和预后中的作用
Author: TIAN JIAWEI ¹ ; HAN SHUHUA
Author Information

1. 东南大学医学院
Keywords: Lung neoplasms; Ribonucleotide reductases; Individualized treatment; Prognosis
From: Chinese Journal of Lung Cancer 2015;(6):381-386
CountryChina
Language:Chinese
Abstract: Lung cancer is one of the most common and highest mortality rates malignant tumors, further, 75%-80% is non-small cell lung cancer (NSCLC). For the majority of patients, lost the chance of radical operation or radiotherapy, che-motherapy is the main treatment. However, because of the diversities of tumor behavior and drug-resistant, the chemotherapy of advanced NSCLC is not optimistic. In recent years, with the application of molecular markers for individual chemotherapy, these patients have achieved prolong life and improved life quality. Individualized chemotherapy based on molecular markers to select the appropriate drug is the problem that needs to be solved. hTe paper gives a brief review on the role of ribonucleo-tide reductase subunit 1 (RRM1) in the treatment and prognosis of advanced NSCLC. Individualized chemotherapy by RRM1 can’t become commonplace for advanced NSCLC and needs further research.